Products Overview

At Alimera Sciences, we are dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our development portfolio, studying compounds to treat early- and late-stage diseases such as diabetic macular edema, wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO).

Today, our primary focus is on ILUVIEN^®, a tiny, cylindrical polyimide tube that contains 190 µg of fluocinolone acetonide (FAc), a corticosteroid with a history of treating ocular diseases. Learn more >>

In addition to activities related to the development of ILUVIEN, we have acquired options to exclusive, worldwide licenses of patent applications covering NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors from Emory University. Learn more >>